Director Clinical Development Operations

Raymond brings over 16 years of global clinical operations leadership, with deep expertise in Phase I–III development program strategy, CRO governance, inspection readiness, and cross-functional execution across immuno-oncology, hematology, rare disease, respiratory, and genetic disorders. He joins K36 Therapeutics from Agios Pharmaceuticals, where, as Clinical Operations Program Lead, he oversaw the end-to-end operational strategy of Global clinical studies supporting Sickle Cell and PKU programs, driving execution from Clinical Study Concept through regulatory submission while aligning trial delivery with corporate development objectives.

​

Throughout his career at organizations including Zenas BioPharma, Constellation Pharmaceuticals, Kadmon, Bioverativ, and Biogen, Raymond has built a track record of delivering complex multi-study programs with operational excellence and quality. His experience spans from vendor selection and contract negotiation, risk-based quality management (RBQM), KPI frameworks and performance governance, inspection readiness and health authority support, development governance, and organizational leadership.

​

Raymond holds a B.S. in Business Administration from Purdue University Global and is certified in Good Clinical Practice (GCP) principles and in TMF/eTMF regulatory expectations.

What drives Raymond goes beyond operational execution. His work at the intersection of clinical science and patient advocacy has profoundly shaped him — deepening his understanding of the human stories behind every clinical program and reinforcing his belief that the patients these programs serve deserve both urgency and compassion. He is committed to ensuring that the voices of underserved patient communities are not only acknowledged but amplified through the work we do every day.